The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults, the company said on Wednesday. 

The drug, Rolapitant, was approved to be used along with other agents to prevent delayed nausea and vomiting associated with initial and repeat courses of chemotherapy, Tesaro said.

Tesaro licensed Rolapitant from Opko Health Inc in December 2010, giving it worldwide rights to develop and market the therapy.